Road To Resilience A Podcast
Ketamine: From Club to Clinic
For the estimated 2.8 million Americans suffering from treatment-resistant depression (TRD), the arrival of esketamine nasal spray in 2019 couldn’t come soon enough. The FDA’s decision to approve the drug, the first ketamine-based antidepressant, was the latest chapter in ketamine’s journey from anesthetic to club drug to antidepressant. It was also the result of two decades of research, including by Dennis S. Charney, MD,* Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and James Murrough, MD, PhD, Associate Professor of Psychiatry and Neuroscience and Director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai. On Road to Resilience, Dr.